A pilot trial of long‐distance shipped, extended‐ and cold‐stored platelets in 100% plasma for cardiothoracic surgical bleeding
Transfusion · 2026
DOI: 10.1111/trf.70076 ↗At a glance
Randomisierte kontrollierte Studie in Transfusion, 2026. Written by Moritz Stolla and 13 co-authors. Institution: Bloodworks Northwest Research Institute, Seattle, Washington, USA. Major MEDLINE topics: Blood Preservation, Platelet Transfusion, Blood Platelets, Cardiac Surgical Procedures. Cited 3 times so far (Crossref); 15 references. Funded by: U.S. Department of Defense.
Abstract (original language)
Background
In this pilot trial, we tested the feasibility of conducting a randomized controlled trial in cardiac surgery patients using extended‐, 100% plasma‐, cold‐stored, and long‐distance‐shipped platelets (CSPs). Study Design and Methods We conducted a single center, controlled, double‐blind pilot study in adult patients undergoing elective redo or complex cardiothoracic surgery. Patients were allocated in a week‐based block randomization scheme to receive either room temperature‐stored platelets (RTPs) or CSPs shipped from a Texas‐based blood center and stored between 10 and 14 days. The primary outcome was defined as the feasibility of recruitment and accrual. Several other secondary endpoints were assessed. All platelet units were screened for aggregates using RTP release criteria.
Results
In a post‐hoc “as treated” analysis, 15 patients received RTPs , and 9 received CSPs (including 3 who received both). We found that most CSPs (58%) were not usable for transfusion due to the presence of aggregates. This resulted in an excess of subjects receiving RTPs ; consequently, the final nine transfused participants were allocated to receive CSPs without randomization. We accrued 0.7 evaluable subjects/month of active enrollment, which was below our desired primary outcome feasibility target of ≥1.2. One death within 28 days occurred in the RTP transfusion group, while none occurred in the CSPs group. In vitro testing yielded contradictory results.
Conclusion
Due to slow recruitment and the abundance of aggregates in CSPs, this pilot trial does not support the feasibility of the study protocol.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Bloodworks Northwest Research Institute, Seattle, Washington, USA.
- Bloodworks Northwest, Medical Services Division, Seattle, Washington, USA.
- Department of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, Washington, USA.
- Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
- Clinical Research Division, Fred Hutch Cancer Institute, Seattle, Washington, USA.
- Stasys Medical Corporation, Seattle, Washington, USA.
ORCID profiles: Moritz Stolla
Funding
- U.S. Department of Defense
Cite
APA
Stolla, M., Bailey, S. L., Chauhan, A., Byrne, D. A., Ting, L., Klotz, P., Pulido, J. N., Lehr, E. J., Youssef, S., Lawrence, J., Limanek, A., Alcorn, K., Ryan, P., & Stout, D. M. (2026). A pilot trial of long‐distance shipped, extended‐ and cold‐stored platelets in 100% plasma for cardiothoracic surgical bleeding. Transfusion. https://doi.org/10.1111/trf.70076
Vancouver
Stolla M, Bailey SL, Chauhan A, Byrne DA, Ting L, Klotz P, et al. A pilot trial of long‐distance shipped, extended‐ and cold‐stored platelets in 100% plasma for cardiothoracic surgical bleeding. Transfusion. 2026. doi:10.1111/trf.70076
BibTeX
@article{Stolla2026,
author = {Stolla, Moritz and Bailey, S Lawrence and Chauhan, Aastha and Byrne, Daire A and Ting, Lucas and Klotz, Patricia and Pulido, Juan N and Lehr, Eric J and Youssef, Samuel and Lawrence, Josh and Limanek, Austin and Alcorn, Kirsten and Ryan, Patrick and Stout, David M},
title = {A pilot trial of long‐distance shipped, extended‐ and cold‐stored platelets in 100% plasma for cardiothoracic surgical bleeding},
journal = {Transfusion},
year = {2026},
doi = {10.1111/trf.70076}
}
EUVIMED